From a therapy perspective, chronic therapies have done exceedingly well for the month of June, with anti-diabetic (32.7%), cardiac (21.1%). The vitamins and nutrients market has also grown at 21.1% for the month, while the respiratory market for the month registered a low growth of 6.1%, said Hari Natarajan, head, pharmaTrac, Aiocd Awacs. He said companies with a strong chronic drug portfolio have expectedly experienced high growth for the month of June.
Sun Pharma, one such company with a heavy tilt towards chronic therapies vis-a-vis acute therapies prone to seasonal fluctuations has grown at a racy 23% for a second consecutive month.
Even for the 12-month ended June, Sun has maintained a healthy growth rate 23% in comparison to its closest rival GSK, which for a similar period grew by 17.8%.
As reported by FE earlier, since early this year Sun and GSK are neck and neck for the spot of third-largest drugmaker by market share.
For the month of June, Sun grabbed a market share of 4.81% of the R5,587 monthly drug market despite a strong show by GSK, which grew at a remarkable 24.9% to command 4.75% market share.
In terms of therapeutic tilt, Sun Pharma has the largest market share of prescription in the segments of psychiatrists, neurologists and cardiologists, and is counted among the top-three leaders in the category of ophthalmologists, orthopedicians, gastroenterologists and nephrologists, according to the company.
Cipla and Abbott grew at a weak 3.8% for the month of June.